NASDAQ:SLNO

Soleno Therapeutics Competitors

$1.15
-0.03 (-2.54 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.12
Now: $1.15
$1.18
50-Day Range
$1.12
MA: $1.63
$2.69
52-Week Range
$1.11
Now: $1.15
$4.39
Volume967,427 shs
Average Volume1.71 million shs
Market Capitalization$91.68 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71

Competitors

Soleno Therapeutics (NASDAQ:SLNO) Vs. EDAP, EYES, BSGM, FONR, IRIX, and NDRA

Should you be buying SLNO stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Soleno Therapeutics, including Edap Tms (EDAP), Second Sight Medical Products (EYES), BioSig Technologies (BSGM), FONAR (FONR), IRIDEX (IRIX), and ENDRA Life Sciences (NDRA).

Edap Tms (NASDAQ:EDAP) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Institutional and Insider Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Edap Tms has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Earnings & Valuation

This table compares Edap Tms and Soleno Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edap Tms$50.23 million5.27$1.69 million$0.06151.33
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64

Edap Tms has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Edap Tms, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Edap Tms and Soleno Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edap Tms00303.00
Soleno Therapeutics00303.00

Edap Tms presently has a consensus target price of $12.50, suggesting a potential upside of 37.67%. Soleno Therapeutics has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Edap Tms.

Profitability

This table compares Edap Tms and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edap Tms-4.03%-11.54%-5.78%
Soleno TherapeuticsN/A-88.69%-51.63%

Summary

Edap Tms beats Soleno Therapeutics on 6 of the 11 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and Second Sight Medical Products (NASDAQ:EYES) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Insider & Institutional Ownership

55.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Second Sight Medical Products shares are held by institutional investors. 74.9% of Soleno Therapeutics shares are held by company insiders. Comparatively, 67.5% of Second Sight Medical Products shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Soleno Therapeutics and Second Sight Medical Products, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soleno Therapeutics00303.00
Second Sight Medical Products0000N/A

Soleno Therapeutics presently has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Second Sight Medical Products.

Valuation & Earnings

This table compares Soleno Therapeutics and Second Sight Medical Products' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64
Second Sight Medical Products$3.38 million50.63$-33,590,000.00($1.91)-3.85

Soleno Therapeutics has higher earnings, but lower revenue than Second Sight Medical Products. Second Sight Medical Products is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Second Sight Medical Products has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Profitability

This table compares Soleno Therapeutics and Second Sight Medical Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soleno TherapeuticsN/A-88.69%-51.63%
Second Sight Medical ProductsN/A-977.63%-291.02%

Summary

Soleno Therapeutics beats Second Sight Medical Products on 9 of the 11 factors compared between the two stocks.

BioSig Technologies (NASDAQ:BSGM) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

18.3% of BioSig Technologies shares are held by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are held by institutional investors. 19.5% of BioSig Technologies shares are held by insiders. Comparatively, 74.9% of Soleno Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for BioSig Technologies and Soleno Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSig Technologies0000N/A
Soleno Therapeutics00303.00

Soleno Therapeutics has a consensus target price of $8.6667, suggesting a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, analysts plainly believe Soleno Therapeutics is more favorable than BioSig Technologies.

Profitability

This table compares BioSig Technologies and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSig TechnologiesN/A-244.64%-213.88%
Soleno TherapeuticsN/A-88.69%-51.63%

Risk & Volatility

BioSig Technologies has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Valuation and Earnings

This table compares BioSig Technologies and Soleno Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSig TechnologiesN/AN/A$-34,060,000.00N/AN/A
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64

Summary

Soleno Therapeutics beats BioSig Technologies on 7 of the 8 factors compared between the two stocks.

Soleno Therapeutics (NASDAQ:SLNO) and FONAR (NASDAQ:FONR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Risk and Volatility

Soleno Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, FONAR has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

55.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 62.1% of FONAR shares are owned by institutional investors. 74.9% of Soleno Therapeutics shares are owned by insiders. Comparatively, 8.6% of FONAR shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Soleno Therapeutics and FONAR's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64
FONAR$85.69 million1.40$8.24 millionN/AN/A

FONAR has higher revenue and earnings than Soleno Therapeutics.

Analyst Ratings

This is a breakdown of current ratings for Soleno Therapeutics and FONAR, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soleno Therapeutics00303.00
FONAR0000N/A

Soleno Therapeutics presently has a consensus price target of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher probable upside, equities analysts plainly believe Soleno Therapeutics is more favorable than FONAR.

Profitability

This table compares Soleno Therapeutics and FONAR's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soleno TherapeuticsN/A-88.69%-51.63%
FONAR8.28%5.57%3.99%

Summary

FONAR beats Soleno Therapeutics on 8 of the 11 factors compared between the two stocks.

IRIDEX (NASDAQ:IRIX) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap computer and technology companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for IRIDEX and Soleno Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IRIDEX00203.00
Soleno Therapeutics00303.00

IRIDEX presently has a consensus target price of $6.50, indicating a potential downside of 15.69%. Soleno Therapeutics has a consensus target price of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than IRIDEX.

Earnings & Valuation

This table compares IRIDEX and Soleno Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IRIDEX$43.45 million2.75$-8,810,000.00($0.64)-12.05
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64

IRIDEX has higher revenue and earnings than Soleno Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

IRIDEX has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

32.6% of IRIDEX shares are owned by institutional investors. Comparatively, 55.4% of Soleno Therapeutics shares are owned by institutional investors. 2.0% of IRIDEX shares are owned by company insiders. Comparatively, 74.9% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares IRIDEX and Soleno Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IRIDEX-21.54%-38.60%-24.99%
Soleno TherapeuticsN/A-88.69%-51.63%

Soleno Therapeutics (NASDAQ:SLNO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Soleno Therapeutics and ENDRA Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Soleno Therapeutics00303.00
ENDRA Life Sciences0000N/A

Soleno Therapeutics presently has a consensus target price of $8.6667, indicating a potential upside of 653.62%. Given Soleno Therapeutics' higher possible upside, equities research analysts clearly believe Soleno Therapeutics is more favorable than ENDRA Life Sciences.

Insider and Institutional Ownership

55.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 2.8% of ENDRA Life Sciences shares are held by institutional investors. 74.9% of Soleno Therapeutics shares are held by company insiders. Comparatively, 9.6% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Soleno Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.

Profitability

This table compares Soleno Therapeutics and ENDRA Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Soleno TherapeuticsN/A-88.69%-51.63%
ENDRA Life SciencesN/A-492.76%-288.58%

Valuation & Earnings

This table compares Soleno Therapeutics and ENDRA Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Soleno TherapeuticsN/AN/A$-30,770,000.00($0.70)-1.64
ENDRA Life Sciences$10,000.009,068.80$-13,310,000.00($2.34)-0.93

ENDRA Life Sciences has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Soleno Therapeutics beats ENDRA Life Sciences on 7 of the 11 factors compared between the two stocks.


Soleno Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Edap Tms logo
EDAP
Edap Tms
1.3$9.08-0.3%$264.61 million$50.23 million-151.33Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$7.36-11.4%$171.12 million$3.38 million-3.85Decrease in Short Interest
Gap Down
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$3.88-4.4%$123.35 millionN/A0.00Gap Down
FONR
FONAR
1.1$18.32-2.9%$120.07 million$85.69 million17.28News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.71-3.0%$119.67 million$43.45 million-14.02Gap Up
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.18-1.8%$90.69 million$10,000.00-1.18Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.79-1.7%$86.77 million$2.39 million-2.27Decrease in Short Interest
Gap Up
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.3$16.90-1.3%$39.06 million$1.50 million-0.97Analyst Upgrade
Increase in Short Interest
News Coverage
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.37-0.4%$32.42 million$5.51 million-0.11Analyst Downgrade
Increase in Short Interest
News Coverage
Viveve Medical logo
VIVE
Viveve Medical
0.9$2.63-5.7%$27.20 million$6.57 million-0.01News Coverage
Gap Down
Star Equity logo
STRR
Star Equity
0.1$2.80-5.4%$13.78 million$114.18 million-0.89Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.